Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression.

Trial Profile

Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Naltrexone (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2017 According to an Immune Therapeutics media release, the company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines. The application will include results of four phase II clinical trials and one bridging trial clinical trial.
    • 26 Oct 2016 According to Immune Therapeutics media release, the Ministry of Health and Prevention Division of Pharmacy in the Republic of Senegal (the "Ministry of Health") accepted for review the Company's New Drug Applications ("NDAs") for LodonalTM as a stand alone or adjunct therapy non-toxic in the treatment of HIV/AIDS, cancer and as an immune booster.
    • 18 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top